Table 6. Patient characteristics stratified by treatment with active vitamin D.
| Characteristic | All patients | No vitamin D | Vitamin D | p-value |
| Clinical data | ||||
| Total (n) | 726 | 222 | 494 | – |
| Male gender (726) | 58.8% | 61.7% | 41.7% | 0.390 |
| BMI (kg/m2)a (291) | 24.0 (12.5–39.1) | 23.8 (12.5–36.5) | 24.0 (16.4–39.1) | 0.556 |
| Age (years)a (726) | 55.7 (16.1–87.0) | 58.8 (16.1–87.0) | 54.6 (16.5–84.9) | 0.001 |
| Primary renal disease (726) | 0.349 | |||
| GN | 23.9% | 25.2% | 23.7% | |
| DN | 16.1% | 16.7% | 15.8% | |
| PCKD | 9.4% | 7.2% | 10.5% | |
| Other (e.g. interstitial nephritis)/unknown | 50.6% | 50.9% | 50.0% | |
| Modality (725) | 0.399 | |||
| CAPD only | 60.1% | 62.0% | 59.1% | |
| APD only | 27.3% | 28.1% | 27.3% | |
| Switchb | 12.6% | 10.0% | 13.6% | |
| Comedication | ||||
| RAAS inhibitors (718) | 63.5% | 54.5% | 67.6% | 0.001 |
| Statins (714) | 43.7% | 40.0% | 45.6% | 0.139 |
| Immunosuppression (715) | 16.9% | 17.6% | 16.6% | 0.758 |
| Calcium-based PB (716) | 52.0% | 49.5% | 53.4% | 0.335 |
| Non calcium-based PB (716) | 40.3% | 26.6% | 46.4% | <0.001 |
| Laboratory data | ||||
| Albumin (447) | <0.001 | |||
| <3500 mg/dl | 35.3% | 55.6% | 28.6% | |
| 3500–5200 mg/dl | 64.7% | 44.4% | 71.4% | |
| Calcium (614) | 0.015 | |||
| <2.10 mmol/l | 21.3% | 28.7% | 18.2% | |
| 2.10–2.37 mmol/l | 49.9% | 44.8% | 52.1% | |
| >2.37 mmol/l | 28.8% | 26.5% | 29.7% | |
| Phosphate (617) | 0.218 | |||
| <1.13 mmol/l | 8.9% | 12.1% | 7.7% | |
| 1.13–1.78 mmol/l | 39.2% | 37.9% | 39.8% | |
| >1.78 mmol/l | 51.9% | 50.0% | 52.6% | |
| Parathyroid hormone (214) | 0.031 | |||
| <150 pg/ml | 32.6% | 40.6% | 28.5% | |
| 150–300 pg/ml | 33.5% | 37.9% | 31.9% | |
| >300 pg/ml | 34.0% | 21.7% | 40.0% | |
| Hemoglobin (622) | 0.071 | |||
| <10 g/dl | 12.4% | 10.8% | 12.9% | |
| 10–12 g/dl | 58.8% | 65.9% | 56.1% | |
| >12 g/dl | 28.8% | 23.2% | 30.9% | |
| Comorbid conditions | ||||
| Diabetes (719) | 24.1% | 25.9% | 23.1% | 0.421 |
| Hypertension (719) | 82.2% | 80.0% | 83.0% | 0.341 |
| Cardiomyopathy (719) | 13.1% | 20.9% | 9.7% | <0.001 |
| Myocardial infarction (719) | 10.2% | 11.8% | 9.5% | 0.353 |
| Cerebrovascular disease (719) | 9.6% | 12.3% | 8.5% | 0.117 |
| Peripheral arterial disease (719) | 13.2% | 18.2% | 11.0% | 0.008 |
a
median and range.
b
switch from CAPD to APD or vice versa. DN; diabetic nephropathy. GN; glomerulonephritis. PB; phosphate binders. PCKD; polycystic kidney disease. A p-value <0.05 was considered as significant. Numbers in brackets in the first column represent the number of patients for who data were available.